Product Highlight - XAVI
10 Jun 2026
- Proven Bioequivalence to Originator with Trusted Efficacy1
- Affordable Long-Term Anticoagulation for NVAF Patients2
- Convenient Fixed Dosing with No Routine INR Monitoring3
References:
1. Clinical Study Report Apixaban (Xavi).
2. Tajik A, Abbasi A, Goudarzi Z, Izadi-Moud A, Varmaghani M. Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran. Clin Cardiol. 2024 Jun;47(6):e24311. doi: 10.1002/clc.24311. PMID: 38923583; PMCID: PMC11194975.
3. Agrawal A, Manna B. Apixaban. [Updated 2024 Feb 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507910/.
For healthcare professionals only.
PHARMANIAGA MARKETING SDN BHD
Company No: 198401005734
No. 7 Lorong Keluli 1B, Kawasan Perindustrian Bukit, Raja Selatan, Seksyen 7,
Selangor Darul Ehsan 40000
Tel: (+60) 3342 9999 • Fax: (+60) 3341 7777
